secwatch.observer — SEC 8-K summary
======================================

Issuer:     PRECIGEN, INC. (PGEN)
CIK:        0001356090
Form:       8-K
Filed at:   2026-05-13T20:22:27+00:00
Accession:  0000950103-26-007158
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Precigen Q1: PAPZIMEOS nets $21.6M revenue; loss narrows to $7.9M
-----------------------------------------------------------------

- Net product revenue from PAPZIMEOS was $21.6M in Q1 2026, first full quarter post-FDA approval.
- Net loss narrowed to $7.9M ($0.02/share) from $54.2M ($0.18/share) in Q1 2025.
- Patient hub enrollment reached ~400 patients; 25% from community settings.
- Cash, equivalents, and investments totaled $56.7M as of March 31, 2026.
- Permanent J-code (J3404) assigned effective April 1, 2026, expected to streamline access.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1356090/000095010326007158/0000950103-26-007158-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1356090/000095010326007158/dp246650_8k.htm
  HTML page:      https://secwatch.observer/filing/0000950103-26-007158

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer